APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

Spinal Muscular Atrophy Medicine

Compare research editions
View pricing & licenses

Selected research

Industry Growth & Trends

Global Spinal Muscular Atrophy Medicine Industry Growth and Trends Forecast to 2032

Report ID 174037410126 December 2025114 pages

Choose your research edition.

Industry ResearchSpinal Muscular Atrophy Medicine Industry Research Report 2026131 pages · $2,950 USDIndustry Growth & TrendsGlobal Spinal Muscular Atrophy Medicine Industry Growth and Trends Forecast to 2032114 pages · $3,450 USDMarket StructureGlobal Spinal Muscular Atrophy Medicine Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032198 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Spinal Muscular Atrophy Medicine Market Outlook and Growth Opportunities 2026208 pages · $4,250 USDMarket Analysis & ForecastGlobal Spinal Muscular Atrophy Medicine Market Analysis and Forecast 2026-2032203 pages · $4,950 USD

Market perspective

The global Spinal Muscular Atrophy Medicine market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.

The North America market for Spinal Muscular Atrophy Medicine is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026-2032.

The Europe market for Spinal Muscular Atrophy Medicine is projected to increase from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Spinal Muscular Atrophy Medicine is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Spinal Muscular Atrophy Medicine include Novartis AG, Astellas Pharma Inc., WAVE Life Sciences Ltd., Vybion, Inc., Voyager Therapeutics, Inc., Sarepta Therapeutics, Inc., Neurotune AG, Neurodyn Inc. and Longevity Biotech, Inc, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

Report Scope

This report provides a structured, data-driven view of the global Spinal Muscular Atrophy Medicine market, combining harmonized quantitative metrics with targeted qualitative insight to support business and growth strategy, market positioning, and capital allocation.

The Spinal Muscular Atrophy Medicine market size, estimates, and forecasts are presented in terms of sales volume (W Units) and revenue (US$ million), with 2025 as the base year and historical and forecast data for 2021-2032. The report segments the global Spinal Muscular Atrophy Medicine market by Type, Application, region/country, and company, provides regional market sizes at the segment level, profiles the competitive landscape and key players and their market ranks, and reviews technology trends and new product developments relevant to Spinal Muscular Atrophy Medicine.

Key Companies & Market Share Insights

This section analyzes the strategies and performance of leading manufacturers in the global Spinal Muscular Atrophy Medicine market, including portfolio focus, innovation and product development, mergers and acquisitions, collaborations, and geographic expansion used to sustain or enhance competitive positions. It also summarizes recent corporate developments and key financial indicators and provides global revenue, price, and sales volume data by manufacturer for 2020-2025, enabling benchmarking of scale, pricing, and market share and supporting assessment of market concentration through indicators such as CR5 and CR10.

Spinal Muscular Atrophy Medicine Market by Company

Novartis AG

Astellas Pharma Inc.

WAVE Life Sciences Ltd.

Vybion, Inc.

Voyager Therapeutics, Inc.

Sarepta Therapeutics, Inc.

Neurotune AG

Neurodyn Inc.

Longevity Biotech, Inc

Ionis Pharmaceuticals, Inc.

GMP-Orphan SAS

Genzyme Corporation

Genethon

F. Hoffmann-La Roche Ltd.

Cytokinetics, Inc. 24

Bioblast Pharma Ltd.

AveXis, Inc.

Spinal Muscular Atrophy Medicine Segment by Type

LMI-070

ND-602

NT-1654

NXD-30001

Nusinersen

Others

Spinal Muscular Atrophy Medicine Segment by Application

Hospital

Clinic

Others

Spinal Muscular Atrophy Medicine Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Spinal Muscular Atrophy Medicine market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Spinal Muscular Atrophy Medicine and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Spinal Muscular Atrophy Medicine.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the study scope of this report, executive summary of market segments by type, market size segments for North America, Europe, Asia Pacific, South America, Middle East & Africa.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Spinal Muscular Atrophy Medicine manufacturers competitive landscape, price, sales, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.

Chapter 4: Sales, revenue of Spinal Muscular Atrophy Medicine in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the future development prospects, and market space in the world.

Chapter 5: Introduces market segments by application, market size segment for North America, Europe, Asia Pacific, South America, Middle East & Africa.

Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 7, 8, 9, 10 and 11: North America, Europe, Asia Pacific, South America, Middle East & Africa, sales and revenue by country.

Chapter 12: Analysis of industrial chain, key raw materials, manufacturing cost, and market dynamics.

Chapter 13: Concluding Insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Major Company of LMI-070 Table 2. Major Company of ND-602 Table 3. Major Company of NT-1654 Table 4. Major Company of NXD-30001 Table 5. Major Company of Nusinersen Table 6. Major Company of Others Table 7. Global Spinal Muscular Atrophy Medicine Sales by Type (2021 VS 2025 VS 2032) & (US$ Million) Table 8. Global Spinal Muscular Atrophy Medicine Sales by Type (2021-2026) & (W Units) Table 9. Global Spinal Muscular Atrophy Medicine Sales Market Share in Volume by Type (2021-2026) Table 10. Global Spinal Muscular Atrophy Medicine Sales by Type (2021-2026) & (US$ Million) Table 11. Global Spinal Muscular Atrophy Medicine Sales Market Share in Value by Type (2021-2026) Table 12. Global Spinal Muscular Atrophy Medicine Price by Type (2021-2026) & (US$/Unit) Table 13. Global Spinal Muscular Atrophy Medicine Sales by Type (2027-2032) & (W Units) Table 14. Global Spinal Muscular Atrophy Medicine Sales Market Share in Volume by Type (2027-2032) Table 15. Global Spinal Muscular Atrophy Medicine Sales by Type (2027-2032) & (US$ Million) Table 16. Global Spinal Muscular Atrophy Medicine Sales Market Share in Value by Type (2027-2032) Table 17. Global Spinal Muscular Atrophy Medicine Price by Type (2027-2032) & (US$/Unit) Table 18. North America Spinal Muscular Atrophy Medicine Sales by Type (2021-2026) & (W Units) Table 19. North America Spinal Muscular Atrophy Medicine Sales by Type (2021-2026) & (US$ Million) Table 20. Europe Spinal Muscular Atrophy Medicine Sales by Type (2021-2026) & (W Units) Table 21. Europe Spinal Muscular Atrophy Medicine Sales by Type (2021-2026) & (US$ Million) Table 22. Asia-Pacific Spinal Muscular Atrophy Medicine Sales by Type (2021-2026) & (W Units) Table 23. Asia-Pacific Spinal Muscular Atrophy Medicine Sales by Type (2021-2026) & (US$ Million) Table 24. Latin America Spinal Muscular Atrophy Medicine Sales by Type (2021-2026) & (W Units) Table 25. Latin America Spinal Muscular Atrophy Medicine Sales by Type (2021-2026) & (US$ Million) Table 26. Middle East and Africa Spinal Muscular Atrophy Medicine Sales by Type (2021-2026) & (W Units) Table 27. Middle East and Africa Spinal Muscular Atrophy Medicine Sales by Type (2021-2026) & (US$ Million) Table 28. Spinal Muscular Atrophy Medicine Industry Trends Table 29. Spinal Muscular Atrophy Medicine Industry Drivers Table 30. Spinal Muscular Atrophy Medicine Industry Opportunities and Challenges Table 31. Spinal Muscular Atrophy Medicine Industry Restraints Table 32. Global Spinal Muscular Atrophy Medicine Sales Revenue by Company (US$ Million) & (2021-2026) Table 33. Global Spinal Muscular Atrophy Medicine Revenue Market Share by Company (2021-2026) Table 34. Global Spinal Muscular Atrophy Medicine Sales by Company (2021-2026) & (W Units) Table 35. Global Spinal Muscular Atrophy Medicine Sales Share by Company (2021-2026) Table 36. Global Spinal Muscular Atrophy Medicine Market Price by Company (2021-2026) & (US$/Unit) Table 37. Global Spinal Muscular Atrophy Medicine Industry Company Ranking, 2024 VS 2025 VS 2026 Table 38. Global Spinal Muscular Atrophy Medicine Major Company Production Sites and Headquarters Table 39. Global Spinal Muscular Atrophy Medicine Company, Product Type & Application Table 40. Global Spinal Muscular Atrophy Medicine Company Establishment Date Table 41. Global Company Market Concentration Ratio (CR5 and HHI) Table 42. Global Spinal Muscular Atrophy Medicine by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 43. Global Spinal Muscular Atrophy Medicine Market Size Comparison by Region (US$ Million): 2021 VS 2025 VS 2032 Table 44. Global Spinal Muscular Atrophy Medicine Sales by Region (2021-2026) & (W Units) Table 45. Global Spinal Muscular Atrophy Medicine Sales Market Share in Volume by Region (2021-2026) Table 46. Global Spinal Muscular Atrophy Medicine Sales by Region (2021-2026) & (US$ Million) Table 47. Global Spinal Muscular Atrophy Medicine Sales Market Share in Value by Region (2021-2026) Table 48. Global Spinal Muscular Atrophy Medicine Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 49. Global Spinal Muscular Atrophy Medicine Sales by Region (2027-2032) & (W Units) Table 50. Global Spinal Muscular Atrophy Medicine Sales Market Share in Volume by Region (2027-2032) Table 51. Global Spinal Muscular Atrophy Medicine Sales by Region (2027-2032) & (US$ Million) Table 52. Global Spinal Muscular Atrophy Medicine Sales Market Share in Value by Region (2027-2032) Table 53. Global Spinal Muscular Atrophy Medicine Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2027-2032) Table 54. Global Spinal Muscular Atrophy Medicine Sales by Application (2021 VS 2025 VS 2032) & (US$ Million) Table 55. Global Spinal Muscular Atrophy Medicine Sales by Application (2021-2026) & (W Units) Table 56. Global Spinal Muscular Atrophy Medicine Sales Market Share in Volume by Application (2021-2026) Table 57. Global Spinal Muscular Atrophy Medicine Sales by Application (2021-2026) & (US$ Million) Table 58. Global Spinal Muscular Atrophy Medicine Sales Market Share in Value by Application (2021-2026) Table 59. Global Spinal Muscular Atrophy Medicine Price by Application (2021-2026) & (US$/Unit) Table 60. Global Spinal Muscular Atrophy Medicine Sales by Application (2027-2032) & (W Units) Table 61. Global Spinal Muscular Atrophy Medicine Sales Market Share in Volume by Application (2027-2032) Table 62. Global Spinal Muscular Atrophy Medicine Sales by Application (2027-2032) & (US$ Million) Table 63. Global Spinal Muscular Atrophy Medicine Sales Market Share in Value by Application (2027-2032) Table 64. Global Spinal Muscular Atrophy Medicine Price by Application (2027-2032) & (US$/Unit) Table 65. North America Spinal Muscular Atrophy Medicine Sales by Application (2021-2026) & (W Units) Table 66. North America Spinal Muscular Atrophy Medicine Sales by Application (2021-2026) & (US$ Million) Table 67. Europe Spinal Muscular Atrophy Medicine Sales by Application (2021-2026) & (W Units) Table 68. Europe Spinal Muscular Atrophy Medicine Sales by Application (2021-2026) & (US$ Million) Table 69. Asia-Pacific Spinal Muscular Atrophy Medicine Sales by Application (2021-2026) & (W Units) Table 70. Asia-Pacific Spinal Muscular Atrophy Medicine Sales by Application (2021-2026) & (US$ Million) Table 71. Latin America Spinal Muscular Atrophy Medicine Sales by Application (2021-2026) & (W Units) Table 72. Latin America Spinal Muscular Atrophy Medicine Sales by Application (2021-2026) & (US$ Million) Table 73. Middle East and Africa Spinal Muscular Atrophy Medicine Sales by Application (2021-2026) & (W Units) Table 74. Middle East and Africa Spinal Muscular Atrophy Medicine Sales by Application (2021-2026) & (US$ Million) Table 75. Novartis AG Company Information Table 76. Novartis AG Business Overview Table 77. Novartis AG Spinal Muscular Atrophy Medicine Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 78. Novartis AG Spinal Muscular Atrophy Medicine Product Portfolio Table 79. Novartis AG Recent Development Table 80. Astellas Pharma Inc. Company Information Table 81. Astellas Pharma Inc. Business Overview Table 82. Astellas Pharma Inc. Spinal Muscular Atrophy Medicine Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 83. Astellas Pharma Inc. Spinal Muscular Atrophy Medicine Product Portfolio Table 84. Astellas Pharma Inc. Recent Development Table 85. WAVE Life Sciences Ltd. Company Information Table 86. WAVE Life Sciences Ltd. Business Overview Table 87. WAVE Life Sciences Ltd. Spinal Muscular Atrophy Medicine Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 88. WAVE Life Sciences Ltd. Spinal Muscular Atrophy Medicine Product Portfolio Table 89. WAVE Life Sciences Ltd. Recent Development Table 90. Vybion, Inc. Company Information Table 91. Vybion, Inc. Business Overview Table 92. Vybion, Inc. Spinal Muscular Atrophy Medicine Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 93. Vybion, Inc. Spinal Muscular Atrophy Medicine Product Portfolio Table 94. Vybion, Inc. Recent Development Table 95. Voyager Therapeutics, Inc. Company Information Table 96. Voyager Therapeutics, Inc. Business Overview Table 97. Voyager Therapeutics, Inc. Spinal Muscular Atrophy Medicine Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 98. Voyager Therapeutics, Inc. Spinal Muscular Atrophy Medicine Product Portfolio Table 99. Voyager Therapeutics, Inc. Recent Development Table 100. Sarepta Therapeutics, Inc. Company Information Table 101. Sarepta Therapeutics, Inc. Business Overview Table 102. Sarepta Therapeutics, Inc. Spinal Muscular Atrophy Medicine Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 103. Sarepta Therapeutics, Inc. Spinal Muscular Atrophy Medicine Product Portfolio Table 104. Sarepta Therapeutics, Inc. Recent Development Table 105. Neurotune AG Company Information Table 106. Neurotune AG Business Overview Table 107. Neurotune AG Spinal Muscular Atrophy Medicine Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 108. Neurotune AG Spinal Muscular Atrophy Medicine Product Portfolio Table 109. Neurotune AG Recent Development Table 110. Neurodyn Inc. Company Information Table 111. Neurodyn Inc. Business Overview Table 112. Neurodyn Inc. Spinal Muscular Atrophy Medicine Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 113. Neurodyn Inc. Spinal Muscular Atrophy Medicine Product Portfolio Table 114. Neurodyn Inc. Recent Development Table 115. Longevity Biotech, Inc Company Information Table 116. Longevity Biotech, Inc Business Overview Table 117. Longevity Biotech, Inc Spinal Muscular Atrophy Medicine Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 118. Longevity Biotech, Inc Spinal Muscular Atrophy Medicine Product Portfolio Table 119. Longevity Biotech, Inc Recent Development Table 120. Ionis Pharmaceuticals, Inc. Company Information Table 121. Ionis Pharmaceuticals, Inc. Business Overview Table 122. Ionis Pharmaceuticals, Inc. Spinal Muscular Atrophy Medicine Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 123. Ionis Pharmaceuticals, Inc. Spinal Muscular Atrophy Medicine Product Portfolio Table 124. Ionis Pharmaceuticals, Inc. Recent Development Table 125. GMP-Orphan SAS Company Information Table 126. GMP-Orphan SAS Business Overview Table 127. GMP-Orphan SAS Spinal Muscular Atrophy Medicine Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 128. GMP-Orphan SAS Spinal Muscular Atrophy Medicine Product Portfolio Table 129. GMP-Orphan SAS Recent Development Table 130. Genzyme Corporation Company Information Table 131. Genzyme Corporation Business Overview Table 132. Genzyme Corporation Spinal Muscular Atrophy Medicine Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 133. Genzyme Corporation Spinal Muscular Atrophy Medicine Product Portfolio Table 134. Genzyme Corporation Recent Development Table 135. Genethon Company Information Table 136. Genethon Business Overview Table 137. Genethon Spinal Muscular Atrophy Medicine Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 138. Genethon Spinal Muscular Atrophy Medicine Product Portfolio Table 139. Genethon Recent Development Table 140. F. Hoffmann-La Roche Ltd. Company Information Table 141. F. Hoffmann-La Roche Ltd. Business Overview Table 142. F. Hoffmann-La Roche Ltd. Spinal Muscular Atrophy Medicine Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 143. F. Hoffmann-La Roche Ltd. Spinal Muscular Atrophy Medicine Product Portfolio Table 144. F. Hoffmann-La Roche Ltd. Recent Development Table 145. Cytokinetics, Inc. 24 Company Information Table 146. Cytokinetics, Inc. 24 Business Overview Table 147. Cytokinetics, Inc. 24 Spinal Muscular Atrophy Medicine Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 148. Cytokinetics, Inc. 24 Spinal Muscular Atrophy Medicine Product Portfolio Table 149. Cytokinetics, Inc. 24 Recent Development Table 150. Bioblast Pharma Ltd. Company Information Table 151. Bioblast Pharma Ltd. Business Overview Table 152. Bioblast Pharma Ltd. Spinal Muscular Atrophy Medicine Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 153. Bioblast Pharma Ltd. Spinal Muscular Atrophy Medicine Product Portfolio Table 154. Bioblast Pharma Ltd. Recent Development Table 155. AveXis, Inc. Company Information Table 156. AveXis, Inc. Business Overview Table 157. AveXis, Inc. Spinal Muscular Atrophy Medicine Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 158. AveXis, Inc. Spinal Muscular Atrophy Medicine Product Portfolio Table 159. AveXis, Inc. Recent Development Table 160. North America Spinal Muscular Atrophy Medicine Market Size Growth Rate (CAGR) by Country (W Units): 2021 VS 2025 VS 2032 Table 161. North America Spinal Muscular Atrophy Medicine Sales by Country (2021-2026) & (W Units) Table 162. North America Spinal Muscular Atrophy Medicine Sales Market Share by Country (2021-2026) Table 163. North America Spinal Muscular Atrophy Medicine Sales Forecast by Country (2027-2032) & (W Units) Table 164. North America Spinal Muscular Atrophy Medicine Sales Market Share Forecast by Country (2027-2032) Table 165. North America Spinal Muscular Atrophy Medicine Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 166. North America Spinal Muscular Atrophy Medicine Market Size by Country (2021-2026) & (US$ Million) Table 167. North America Spinal Muscular Atrophy Medicine Market Share by Country (2021-2026) Table 168. North America Spinal Muscular Atrophy Medicine Market Size Forecast by Country (2027-2032) & (US$ Million) Table 169. North America Spinal Muscular Atrophy Medicine Market Share Forecast by Country (2027-2032) Table 170. Europe Spinal Muscular Atrophy Medicine Market Size Growth Rate (CAGR) by Country (W Units): 2021 VS 2025 VS 2032 Table 171. Europe Spinal Muscular Atrophy Medicine Sales by Country (2021-2026) & (W Units) Table 172. Europe Spinal Muscular Atrophy Medicine Sales Market Share by Country (2021-2026) Table 173. Europe Spinal Muscular Atrophy Medicine Sales Forecast by Country (2027-2032) & (W Units) Table 174. Europe Spinal Muscular Atrophy Medicine Sales Market Share Forecast by Country (2027-2032) Table 175. Europe Spinal Muscular Atrophy Medicine Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 176. Europe Spinal Muscular Atrophy Medicine Market Size by Country (2021-2026) & (US$ Million) Table 177. Europe Spinal Muscular Atrophy Medicine Market Share by Country (2021-2026) Table 178. Europe Spinal Muscular Atrophy Medicine Market Size Forecast by Country (2027-2032) & (US$ Million) Table 179. Europe Spinal Muscular Atrophy Medicine Market Share Forecast by Country (2027-2032) Table 180. Asia-Pacific Spinal Muscular Atrophy Medicine Market Size Growth Rate (CAGR) by Country (W Units): 2021 VS 2025 VS 2032 Table 181. Asia-Pacific Spinal Muscular Atrophy Medicine Sales by Country (2021-2026) & (W Units) Table 182. Asia-Pacific Spinal Muscular Atrophy Medicine Sales Market Share by Country (2021-2026) Table 183. Asia-Pacific Spinal Muscular Atrophy Medicine Sales Forecast by Country (2027-2032) & (W Units) Table 184. Asia-Pacific Spinal Muscular Atrophy Medicine Sales Market Share Forecast by Country (2027-2032) Table 185. Asia-Pacific Spinal Muscular Atrophy Medicine Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 186. Asia-Pacific Spinal Muscular Atrophy Medicine Market Size by Country (2021-2026) & (US$ Million) Table 187. Asia-Pacific Spinal Muscular Atrophy Medicine Market Share by Country (2021-2026) Table 188. Asia-Pacific Spinal Muscular Atrophy Medicine Market Size Forecast by Country (2027-2032) & (US$ Million) Table 189. Asia-Pacific Spinal Muscular Atrophy Medicine Market Share Forecast by Country (2027-2032) Table 190. Latin America Spinal Muscular Atrophy Medicine Market Size Growth Rate (CAGR) by Country (W Units): 2021 VS 2025 VS 2032 Table 191. Latin America Spinal Muscular Atrophy Medicine Sales by Country (2021-2026) & (W Units) Table 192. Latin America Spinal Muscular Atrophy Medicine Sales Market Share by Country (2021-2026) Table 193. Latin America Spinal Muscular Atrophy Medicine Sales Forecast by Country (2027-2032) & (W Units) Table 194. Latin America Spinal Muscular Atrophy Medicine Sales Market Share Forecast by Country (2027-2032) Table 195. Latin America Spinal Muscular Atrophy Medicine Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 196. Latin America Spinal Muscular Atrophy Medicine Market Size by Country (2021-2026) & (US$ Million) Table 197. Latin America Spinal Muscular Atrophy Medicine Market Share by Country (2021-2026) Table 198. Latin America Spinal Muscular Atrophy Medicine Market Size Forecast by Country (2027-2032) & (US$ Million) Table 199. Latin America Spinal Muscular Atrophy Medicine Market Share Forecast by Country (2027-2032) Table 200. Middle East and Africa Spinal Muscular Atrophy Medicine Market Size Growth Rate (CAGR) by Country (W Units): 2021 VS 2025 VS 2032 Table 201. Middle East and Africa Spinal Muscular Atrophy Medicine Sales by Country (2021-2026) & (W Units) Table 202. Middle East and Africa Spinal Muscular Atrophy Medicine Sales Market Share by Country (2021-2026) Table 203. Middle East and Africa Spinal Muscular Atrophy Medicine Sales Forecast by Country (2027-2032) & (W Units) Table 204. Middle East and Africa Spinal Muscular Atrophy Medicine Sales Market Share Forecast by Country (2027-2032) Table 205. Middle East and Africa Spinal Muscular Atrophy Medicine Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 206. Middle East and Africa Spinal Muscular Atrophy Medicine Market Size by Country (2021-2026) & (US$ Million) Table 207. Middle East and Africa Spinal Muscular Atrophy Medicine Market Share by Country (2021-2026) Table 208. Middle East and Africa Spinal Muscular Atrophy Medicine Market Size Forecast by Country (2027-2032) & (US$ Million) Table 209. Middle East and Africa Spinal Muscular Atrophy Medicine Market Share Forecast by Country (2027-2032) Table 210. Key Raw Materials Table 211. Raw Materials Key Suppliers Table 212. Spinal Muscular Atrophy Medicine Distributors List Table 213. Spinal Muscular Atrophy Medicine Customers List Table 214. Research Programs/Design for This Report Table 215. Authors List of This Report Table 216. Secondary Sources Table 217. Primary Sources List of Figures Figure 1. Spinal Muscular Atrophy Medicine Image Figure 2. Global Spinal Muscular Atrophy Medicine Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Spinal Muscular Atrophy Medicine Market Size (2021-2032) & (US$ Million) Figure 4. Global Spinal Muscular Atrophy Medicine Sales (2021-2032) & (W Units) Figure 5. LMI-070 Image Figure 6. Global LMI-070 Sales YoY Growth (2021-2032) & (W Units) Figure 7. ND-602 Image Figure 8. Global ND-602 Sales YoY Growth (2021-2032) & (W Units) Figure 9. NT-1654 Image Figure 10. Global NT-1654 Sales YoY Growth (2021-2032) & (W Units) Figure 11. NXD-30001 Image Figure 12. Global NXD-30001 Sales YoY Growth (2021-2032) & (W Units) Figure 13. Nusinersen Image Figure 14. Global Nusinersen Sales YoY Growth (2021-2032) & (W Units) Figure 15. Others Image Figure 16. Global Others Sales YoY Growth (2021-2032) & (W Units) Figure 17. Global Spinal Muscular Atrophy Medicine Market Size Overview by Type (2021-2032) & (US$ Million) Figure 18. Global Spinal Muscular Atrophy Medicine Market Share by Type 2025 VS 2032 Figure 19. North America Spinal Muscular Atrophy Medicine Sales Market Share in Volume by Type in 2025 Figure 20. North America Spinal Muscular Atrophy Medicine Sales Market Share in Value by Type in 2025 Figure 21. Europe Spinal Muscular Atrophy Medicine Sales Market Share in Volume by Type in 2025 Figure 22. Europe Spinal Muscular Atrophy Medicine Sales Market Share in Value by Type in 2025 Figure 23. Asia-Pacific Spinal Muscular Atrophy Medicine Sales Market Share in Volume by Type in 2025 Figure 24. Asia-Pacific Spinal Muscular Atrophy Medicine Sales Market Share in Value by Type in 2025 Figure 25. Latin America Spinal Muscular Atrophy Medicine Sales Market Share in Volume by Type in 2025 Figure 26. Latin America Spinal Muscular Atrophy Medicine Sales Market Share in Value by Type in 2025 Figure 27. Middle East and Africa Spinal Muscular Atrophy Medicine Sales Market Share in Volume by Type in 2025 Figure 28. Middle East and Africa Spinal Muscular Atrophy Medicine Sales Market Share in Value by Type in 2025 Figure 29. Global Top 5 and 10 Spinal Muscular Atrophy Medicine Players Market Share by Revenue in 2025 Figure 30. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 31. Hospital Image Figure 32. Global Hospital Sales YoY Growth (2021-2032) & (W Units) Figure 33. Clinic Image Figure 34. Global Clinic Sales YoY Growth (2021-2032) & (W Units) Figure 35. Others Image Figure 36. Global Others Sales YoY Growth (2021-2032) & (W Units) Figure 37. Global Spinal Muscular Atrophy Medicine Market Size Overview by Application (2021-2032) & (US$ Million) Figure 38. Global Spinal Muscular Atrophy Medicine Market Share by Application 2025 VS 2032 Figure 39. North America Spinal Muscular Atrophy Medicine Sales Market Share in Volume by Application in 2025 Figure 40. North America Spinal Muscular Atrophy Medicine Sales Market Share in Value by Application in 2025 Figure 41. Europe Spinal Muscular Atrophy Medicine Sales Market Share in Volume by Application in 2025 Figure 42. Europe Spinal Muscular Atrophy Medicine Sales Market Share in Value by Application in 2025 Figure 43. Asia-Pacific Spinal Muscular Atrophy Medicine Sales Market Share in Volume by Application in 2025 Figure 44. Asia-Pacific Spinal Muscular Atrophy Medicine Sales Market Share in Value by Application in 2025 Figure 45. Latin America Spinal Muscular Atrophy Medicine Sales Market Share in Volume by Application in 2025 Figure 46. Latin America Spinal Muscular Atrophy Medicine Sales Market Share in Value by Application in 2025 Figure 47. Middle East and Africa Spinal Muscular Atrophy Medicine Sales Market Share in Volume by Application in 2025 Figure 48. Middle East and Africa Spinal Muscular Atrophy Medicine Sales Market Share in Value by Application in 2025 Figure 49. North America Spinal Muscular Atrophy Medicine Sales by Country: 2021 VS 2025 VS 2032 (W Units) Figure 50. North America Spinal Muscular Atrophy Medicine Sales Share by Country: 2021 VS 2025 VS 2032 Figure 51. North America Spinal Muscular Atrophy Medicine Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 52. North America Spinal Muscular Atrophy Medicine Market Share by Country: 2021 VS 2025 VS 2032 Figure 53. Europe Spinal Muscular Atrophy Medicine Sales by Country: 2021 VS 2025 VS 2032 (W Units) Figure 54. Europe Spinal Muscular Atrophy Medicine Sales Share by Country: 2021 VS 2025 VS 2032 Figure 55. Europe Spinal Muscular Atrophy Medicine Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 56. Europe Spinal Muscular Atrophy Medicine Market Share by Country: 2021 VS 2025 VS 2032 Figure 57. Asia-Pacific Spinal Muscular Atrophy Medicine Sales by Country: 2021 VS 2025 VS 2032 (W Units) Figure 58. Asia-Pacific Spinal Muscular Atrophy Medicine Sales Share by Country: 2021 VS 2025 VS 2032 Figure 59. Asia-Pacific Spinal Muscular Atrophy Medicine Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 60. Asia-Pacific Spinal Muscular Atrophy Medicine Market Share by Country: 2021 VS 2025 VS 2032 Figure 61. Latin America Spinal Muscular Atrophy Medicine Sales by Country: 2021 VS 2025 VS 2032 (W Units) Figure 62. Latin America Spinal Muscular Atrophy Medicine Sales Share by Country: 2021 VS 2025 VS 2032 Figure 63. Latin America Spinal Muscular Atrophy Medicine Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 64. Latin America Spinal Muscular Atrophy Medicine Market Share by Country: 2021 VS 2025 VS 2032 Figure 65. Middle East and Africa Spinal Muscular Atrophy Medicine Sales by Country: 2021 VS 2025 VS 2032 (W Units) Figure 66. Middle East and Africa Spinal Muscular Atrophy Medicine Sales Share by Country: 2021 VS 2025 VS 2032 Figure 67. Middle East and Africa Spinal Muscular Atrophy Medicine Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 68. Middle East and Africa Spinal Muscular Atrophy Medicine Market Share by Country: 2021 VS 2025 VS 2032 Figure 69. Spinal Muscular Atrophy Medicine Value Chain Figure 70. Key Raw Materials Price Figure 71. Manufacturing Cost Structure Figure 72. Spinal Muscular Atrophy Medicine Production Mode & Process Figure 73. Direct Comparison with Distribution Share Figure 74. Distributors Profiles Figure 75. Years Considered Figure 76. Research Process Figure 77. Key Executives Interviewed

Scope & coverage.

Types
  • LMI-070
  • ND-602
  • NT-1654
  • NXD-30001
  • Nusinersen
  • Others
Applications
  • Hospital
  • Clinic
  • Others
Companies covered
  • Novartis AG
  • Astellas Pharma Inc.
  • WAVE Life Sciences Ltd.
  • Vybion, Inc.
  • Voyager Therapeutics, Inc.
  • Sarepta Therapeutics, Inc.
  • Neurotune AG
  • Neurodyn Inc.
  • Longevity Biotech, Inc
  • Ionis Pharmaceuticals, Inc.
  • GMP-Orphan SAS
  • Genzyme Corporation
  • Genethon
  • F. Hoffmann-La Roche Ltd.
  • Cytokinetics, Inc. 24
  • Bioblast Pharma Ltd.
  • AveXis, Inc.

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Spinal Muscular Atrophy Medicine Market Size Estimates and Forecasts (2021-2032)
  4. 1.2.2 Global Spinal Muscular Atrophy Medicine Sales Estimates and Forecasts (2021-2032)
  5. 1.3 Spinal Muscular Atrophy Medicine Market by Type
  6. 1.3.1 LMI-070
  7. 1.3.2 ND-602
  8. 1.3.3 NT-1654
  9. 1.3.4 NXD-30001
  10. 1.3.5 Nusinersen
  11. 1.3.6 Others
  12. 1.4 Global Spinal Muscular Atrophy Medicine Market Size by Type
  13. 1.4.1 Global Spinal Muscular Atrophy Medicine Market Size Overview by Type (2021-2032)
  14. 1.4.2 Global Spinal Muscular Atrophy Medicine Historic Market Size Review by Type (2021-2026)
  15. 1.4.3 Global Spinal Muscular Atrophy Medicine Forecasted Market Size by Type (2027-2032)
  16. 1.5 Key Regions Market Size by Type
  17. 1.5.1 North America Spinal Muscular Atrophy Medicine Sales Breakdown by Type (2021-2026)
  18. 1.5.2 Europe Spinal Muscular Atrophy Medicine Sales Breakdown by Type (2021-2026)
  19. 1.5.3 Asia-Pacific Spinal Muscular Atrophy Medicine Sales Breakdown by Type (2021-2026)
  20. 1.5.4 South America Spinal Muscular Atrophy Medicine Sales Breakdown by Type (2021-2026)
  21. 1.5.5 Middle East and Africa Spinal Muscular Atrophy Medicine Sales Breakdown by Type (2021-2026)
2 Global Market Dynamics
  1. 2.1 Spinal Muscular Atrophy Medicine Industry Trends
  2. 2.2 Spinal Muscular Atrophy Medicine Industry Drivers
  3. 2.3 Spinal Muscular Atrophy Medicine Industry Opportunities and Challenges
  4. 2.4 Spinal Muscular Atrophy Medicine Industry Restraints
3 Market Competitive Landscape by Company
  1. 3.1 Global Top Players by Spinal Muscular Atrophy Medicine Revenue (2021-2026)
  2. 3.2 Global Top Players by Spinal Muscular Atrophy Medicine Sales (2021-2026)
  3. 3.3 Global Top Players by Spinal Muscular Atrophy Medicine Price (2021-2026)
  4. 3.4 Global Spinal Muscular Atrophy Medicine Industry Company Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Spinal Muscular Atrophy Medicine Major Company Production Sites & Headquarters
  6. 3.6 Global Spinal Muscular Atrophy Medicine Company, Product Type & Application
  7. 3.7 Global Spinal Muscular Atrophy Medicine Company Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Spinal Muscular Atrophy Medicine Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Spinal Muscular Atrophy Medicine Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Spinal Muscular Atrophy Medicine Tier 1, Tier 2, and Tier 3
4 Spinal Muscular Atrophy Medicine Regional Status and Outlook
  1. 4.1 Global Spinal Muscular Atrophy Medicine Market Size and CAGR by Region: 2021 VS 2025 VS 2032
  2. 4.2 Global Spinal Muscular Atrophy Medicine Historic Market Size by Region
  3. 4.2.1 Global Spinal Muscular Atrophy Medicine Sales in Volume by Region (2021-2026)
  4. 4.2.2 Global Spinal Muscular Atrophy Medicine Sales in Value by Region (2021-2026)
  5. 4.2.3 Global Spinal Muscular Atrophy Medicine Sales (Volume & Value), Price and Gross Margin (2021-2026)
  6. 4.3 Global Spinal Muscular Atrophy Medicine Forecasted Market Size by Region
  7. 4.3.1 Global Spinal Muscular Atrophy Medicine Sales in Volume by Region (2027-2032)
  8. 4.3.2 Global Spinal Muscular Atrophy Medicine Sales in Value by Region (2027-2032)
  9. 4.3.3 Global Spinal Muscular Atrophy Medicine Sales (Volume & Value), Price and Gross Margin (2027-2032)
5 Spinal Muscular Atrophy Medicine by Application
  1. 5.1 Spinal Muscular Atrophy Medicine Market by Application
  2. 5.1.1 Hospital
  3. 5.1.2 Clinic
  4. 5.1.3 Others
  5. 5.2 Global Spinal Muscular Atrophy Medicine Market Size by Application
  6. 5.2.1 Global Spinal Muscular Atrophy Medicine Market Size Overview by Application (2021-2032)
  7. 5.2.2 Global Spinal Muscular Atrophy Medicine Historic Market Size Review by Application (2021-2026)
  8. 5.2.3 Global Spinal Muscular Atrophy Medicine Forecasted Market Size by Application (2027-2032)
  9. 5.3 Key Regions Market Size by Application
  10. 5.3.1 North America Spinal Muscular Atrophy Medicine Sales Breakdown by Application (2021-2026)
  11. 5.3.2 Europe Spinal Muscular Atrophy Medicine Sales Breakdown by Application (2021-2026)
  12. 5.3.3 Asia-Pacific Spinal Muscular Atrophy Medicine Sales Breakdown by Application (2021-2026)
  13. 5.3.4 South America Spinal Muscular Atrophy Medicine Sales Breakdown by Application (2021-2026)
  14. 5.3.5 Middle East and Africa Spinal Muscular Atrophy Medicine Sales Breakdown by Application (2021-2026)
6 Company Profiles
  1. 6.1 Novartis AG
  2. 6.1.1 Novartis AG Company Information
  3. 6.1.2 Novartis AG Business Overview
  4. 6.1.3 Novartis AG Spinal Muscular Atrophy Medicine Sales, Revenue and Gross Margin (2021-2026)
  5. 6.1.4 Novartis AG Spinal Muscular Atrophy Medicine Product Portfolio
  6. 6.1.5 Novartis AG Recent Developments
  7. 6.2 Astellas Pharma Inc.
  8. 6.2.1 Astellas Pharma Inc. Company Information
  9. 6.2.2 Astellas Pharma Inc. Business Overview
  10. 6.2.3 Astellas Pharma Inc. Spinal Muscular Atrophy Medicine Sales, Revenue and Gross Margin (2021-2026)
  11. 6.2.4 Astellas Pharma Inc. Spinal Muscular Atrophy Medicine Product Portfolio
  12. 6.2.5 Astellas Pharma Inc. Recent Developments
  13. 6.3 WAVE Life Sciences Ltd.
  14. 6.3.1 WAVE Life Sciences Ltd. Company Information
  15. 6.3.2 WAVE Life Sciences Ltd. Business Overview
  16. 6.3.3 WAVE Life Sciences Ltd. Spinal Muscular Atrophy Medicine Sales, Revenue and Gross Margin (2021-2026)
  17. 6.3.4 WAVE Life Sciences Ltd. Spinal Muscular Atrophy Medicine Product Portfolio
  18. 6.3.5 WAVE Life Sciences Ltd. Recent Developments
  19. 6.4 Vybion, Inc.
  20. 6.4.1 Vybion, Inc. Company Information
  21. 6.4.2 Vybion, Inc. Business Overview
  22. 6.4.3 Vybion, Inc. Spinal Muscular Atrophy Medicine Sales, Revenue and Gross Margin (2021-2026)
  23. 6.4.4 Vybion, Inc. Spinal Muscular Atrophy Medicine Product Portfolio
  24. 6.4.5 Vybion, Inc. Recent Developments
  25. 6.5 Voyager Therapeutics, Inc.
  26. 6.5.1 Voyager Therapeutics, Inc. Company Information
  27. 6.5.2 Voyager Therapeutics, Inc. Business Overview
  28. 6.5.3 Voyager Therapeutics, Inc. Spinal Muscular Atrophy Medicine Sales, Revenue and Gross Margin (2021-2026)
  29. 6.5.4 Voyager Therapeutics, Inc. Spinal Muscular Atrophy Medicine Product Portfolio
  30. 6.5.5 Voyager Therapeutics, Inc. Recent Developments
  31. 6.6 Sarepta Therapeutics, Inc.
  32. 6.6.1 Sarepta Therapeutics, Inc. Company Information
  33. 6.6.2 Sarepta Therapeutics, Inc. Business Overview
  34. 6.6.3 Sarepta Therapeutics, Inc. Spinal Muscular Atrophy Medicine Sales, Revenue and Gross Margin (2021-2026)
  35. 6.6.4 Sarepta Therapeutics, Inc. Spinal Muscular Atrophy Medicine Product Portfolio
  36. 6.6.5 Sarepta Therapeutics, Inc. Recent Developments
  37. 6.7 Neurotune AG
  38. 6.7.1 Neurotune AG Company Information
  39. 6.7.2 Neurotune AG Business Overview
  40. 6.7.3 Neurotune AG Spinal Muscular Atrophy Medicine Sales, Revenue and Gross Margin (2021-2026)
  41. 6.7.4 Neurotune AG Spinal Muscular Atrophy Medicine Product Portfolio
  42. 6.7.5 Neurotune AG Recent Developments
  43. 6.8 Neurodyn Inc.
  44. 6.8.1 Neurodyn Inc. Company Information
  45. 6.8.2 Neurodyn Inc. Business Overview
  46. 6.8.3 Neurodyn Inc. Spinal Muscular Atrophy Medicine Sales, Revenue and Gross Margin (2021-2026)
  47. 6.8.4 Neurodyn Inc. Spinal Muscular Atrophy Medicine Product Portfolio
  48. 6.8.5 Neurodyn Inc. Recent Developments
  49. 6.9 Longevity Biotech, Inc
  50. 6.9.1 Longevity Biotech, Inc Company Information
  51. 6.9.2 Longevity Biotech, Inc Business Overview
  52. 6.9.3 Longevity Biotech, Inc Spinal Muscular Atrophy Medicine Sales, Revenue and Gross Margin (2021-2026)
  53. 6.9.4 Longevity Biotech, Inc Spinal Muscular Atrophy Medicine Product Portfolio
  54. 6.9.5 Longevity Biotech, Inc Recent Developments
  55. 6.10 Ionis Pharmaceuticals, Inc.
  56. 6.10.1 Ionis Pharmaceuticals, Inc. Company Information
  57. 6.10.2 Ionis Pharmaceuticals, Inc. Business Overview
  58. 6.10.3 Ionis Pharmaceuticals, Inc. Spinal Muscular Atrophy Medicine Sales, Revenue and Gross Margin (2021-2026)
  59. 6.10.4 Ionis Pharmaceuticals, Inc. Spinal Muscular Atrophy Medicine Product Portfolio
  60. 6.10.5 Ionis Pharmaceuticals, Inc. Recent Developments
  61. 6.11 GMP-Orphan SAS
  62. 6.11.1 GMP-Orphan SAS Company Information
  63. 6.11.2 GMP-Orphan SAS Business Overview
  64. 6.11.3 GMP-Orphan SAS Spinal Muscular Atrophy Medicine Sales, Revenue and Gross Margin (2021-2026)
  65. 6.11.4 GMP-Orphan SAS Spinal Muscular Atrophy Medicine Product Portfolio
  66. 6.11.5 GMP-Orphan SAS Recent Developments
  67. 6.12 Genzyme Corporation
  68. 6.12.1 Genzyme Corporation Company Information
  69. 6.12.2 Genzyme Corporation Business Overview
  70. 6.12.3 Genzyme Corporation Spinal Muscular Atrophy Medicine Sales, Revenue and Gross Margin (2021-2026)
  71. 6.12.4 Genzyme Corporation Spinal Muscular Atrophy Medicine Product Portfolio
  72. 6.12.5 Genzyme Corporation Recent Developments
  73. 6.13 Genethon
  74. 6.13.1 Genethon Company Information
  75. 6.13.2 Genethon Business Overview
  76. 6.13.3 Genethon Spinal Muscular Atrophy Medicine Sales, Revenue and Gross Margin (2021-2026)
  77. 6.13.4 Genethon Spinal Muscular Atrophy Medicine Product Portfolio
  78. 6.13.5 Genethon Recent Developments
  79. 6.14 F. Hoffmann-La Roche Ltd.
  80. 6.14.1 F. Hoffmann-La Roche Ltd. Company Information
  81. 6.14.2 F. Hoffmann-La Roche Ltd. Business Overview
  82. 6.14.3 F. Hoffmann-La Roche Ltd. Spinal Muscular Atrophy Medicine Sales, Revenue and Gross Margin (2021-2026)
  83. 6.14.4 F. Hoffmann-La Roche Ltd. Spinal Muscular Atrophy Medicine Product Portfolio
  84. 6.14.5 F. Hoffmann-La Roche Ltd. Recent Developments
  85. 6.15 Cytokinetics, Inc. 24
  86. 6.15.1 Cytokinetics, Inc. 24 Company Information
  87. 6.15.2 Cytokinetics, Inc. 24 Business Overview
  88. 6.15.3 Cytokinetics, Inc. 24 Spinal Muscular Atrophy Medicine Sales, Revenue and Gross Margin (2021-2026)
  89. 6.15.4 Cytokinetics, Inc. 24 Spinal Muscular Atrophy Medicine Product Portfolio
  90. 6.15.5 Cytokinetics, Inc. 24 Recent Developments
  91. 6.16 Bioblast Pharma Ltd.
  92. 6.16.1 Bioblast Pharma Ltd. Company Information
  93. 6.16.2 Bioblast Pharma Ltd. Business Overview
  94. 6.16.3 Bioblast Pharma Ltd. Spinal Muscular Atrophy Medicine Sales, Revenue and Gross Margin (2021-2026)
  95. 6.16.4 Bioblast Pharma Ltd. Spinal Muscular Atrophy Medicine Product Portfolio
  96. 6.16.5 Bioblast Pharma Ltd. Recent Developments
  97. 6.17 AveXis, Inc.
  98. 6.17.1 AveXis, Inc. Company Information
  99. 6.17.2 AveXis, Inc. Business Overview
  100. 6.17.3 AveXis, Inc. Spinal Muscular Atrophy Medicine Sales, Revenue and Gross Margin (2021-2026)
  101. 6.17.4 AveXis, Inc. Spinal Muscular Atrophy Medicine Product Portfolio
  102. 6.17.5 AveXis, Inc. Recent Developments
7 North America by Country
  1. 7.1 North America Spinal Muscular Atrophy Medicine Sales by Country
  2. 7.1.1 North America Spinal Muscular Atrophy Medicine Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 7.1.2 North America Spinal Muscular Atrophy Medicine Sales by Country (2021-2026)
  4. 7.1.3 North America Spinal Muscular Atrophy Medicine Sales Forecast by Country (2027-2032)
  5. 7.2 North America Spinal Muscular Atrophy Medicine Market Size by Country
  6. 7.2.1 North America Spinal Muscular Atrophy Medicine Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 7.2.2 North America Spinal Muscular Atrophy Medicine Market Size by Country (2021-2026)
  8. 7.2.3 North America Spinal Muscular Atrophy Medicine Market Size Forecast by Country (2027-2032)
8 Europe by Country
  1. 8.1 Europe Spinal Muscular Atrophy Medicine Sales by Country
  2. 8.1.1 Europe Spinal Muscular Atrophy Medicine Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 8.1.2 Europe Spinal Muscular Atrophy Medicine Sales by Country (2021-2026)
  4. 8.1.3 Europe Spinal Muscular Atrophy Medicine Sales Forecast by Country (2027-2032)
  5. 8.2 Europe Spinal Muscular Atrophy Medicine Market Size by Country
  6. 8.2.1 Europe Spinal Muscular Atrophy Medicine Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 8.2.2 Europe Spinal Muscular Atrophy Medicine Market Size by Country (2021-2026)
  8. 8.2.3 Europe Spinal Muscular Atrophy Medicine Market Size Forecast by Country (2027-2032)
9 Asia-Pacific by Country
  1. 9.1 Asia-Pacific Spinal Muscular Atrophy Medicine Sales by Country
  2. 9.1.1 Asia-Pacific Spinal Muscular Atrophy Medicine Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 9.1.2 Asia-Pacific Spinal Muscular Atrophy Medicine Sales by Country (2021-2026)
  4. 9.1.3 Asia-Pacific Spinal Muscular Atrophy Medicine Sales Forecast by Country (2027-2032)
  5. 9.2 Asia-Pacific Spinal Muscular Atrophy Medicine Market Size by Country
  6. 9.2.1 Asia-Pacific Spinal Muscular Atrophy Medicine Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 9.2.2 Asia-Pacific Spinal Muscular Atrophy Medicine Market Size by Country (2021-2026)
  8. 9.2.3 Asia-Pacific Spinal Muscular Atrophy Medicine Market Size Forecast by Country (2027-2032)
10 South America by Country
  1. 10.1 South America Spinal Muscular Atrophy Medicine Sales by Country
  2. 10.1.1 South America Spinal Muscular Atrophy Medicine Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 10.1.2 South America Spinal Muscular Atrophy Medicine Sales by Country (2021-2026)
  4. 10.1.3 South America Spinal Muscular Atrophy Medicine Sales Forecast by Country (2027-2032)
  5. 10.2 South America Spinal Muscular Atrophy Medicine Market Size by Country
  6. 10.2.1 South America Spinal Muscular Atrophy Medicine Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 10.2.2 South America Spinal Muscular Atrophy Medicine Market Size by Country (2021-2026)
  8. 10.2.3 South America Spinal Muscular Atrophy Medicine Market Size Forecast by Country (2027-2032)
11 Middle East and Africa by Country
  1. 11.1 Middle East and Africa Spinal Muscular Atrophy Medicine Sales by Country
  2. 11.1.1 Middle East and Africa Spinal Muscular Atrophy Medicine Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 11.1.2 Middle East and Africa Spinal Muscular Atrophy Medicine Sales by Country (2021-2026)
  4. 11.1.3 Middle East and Africa Spinal Muscular Atrophy Medicine Sales Forecast by Country (2027-2032)
  5. 11.2 Middle East and Africa Spinal Muscular Atrophy Medicine Market Size by Country
  6. 11.2.1 Middle East and Africa Spinal Muscular Atrophy Medicine Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 11.2.2 Middle East and Africa Spinal Muscular Atrophy Medicine Market Size by Country (2021-2026)
  8. 11.2.3 Middle East and Africa Spinal Muscular Atrophy Medicine Market Size Forecast by Country (2027-2032)
12 Value Chain and Sales Channels Analysis
  1. 12.1 Spinal Muscular Atrophy Medicine Value Chain Analysis
  2. 12.1.1 Spinal Muscular Atrophy Medicine Key Raw Materials
  3. 12.1.2 Key Raw Materials Price
  4. 12.1.3 Raw Materials Key Suppliers
  5. 12.1.4 Manufacturing Cost Structure
  6. 12.1.5 Spinal Muscular Atrophy Medicine Production Mode & Process
  7. 12.2 Spinal Muscular Atrophy Medicine Sales Channels Analysis
  8. 12.2.1 Direct Comparison with Distribution Share
  9. 12.2.2 Spinal Muscular Atrophy Medicine Distributors
  10. 12.2.3 Spinal Muscular Atrophy Medicine Customers
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources
    8. 14.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,450USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst